The Institute of Metabolic Science-Metabolic Research Laboratories (IMS-MRL) and its embedded Medical Research Council (MRC) Metabolic Diseases Unit investigate the mechanisms through which metabolic health is maintained and how this is disturbed in disease. We seek to use that knowledge to aid better treatment and prevention of obesity, Type 2 diabetes and related endocrine and metabolic diseases.
IMS-MRL research groups encompass skills in genetics, cell biology, cell signalling, neuroendocrinology, bioenergetics, human and animal physiology, experimental medicine and clinical trials.
Latest news
Setmelanotide now licensed to treat children with genetic obesity from age 2
11 December 2024
The Farooqi team recently worked with colleagues across the world to complete a 12 month Phase 3 clinical trial of the Melanocortin 4 receptor agonist, Setmelanotide, in very young children (aged 2-5 years) with severe obesity due to genetic conditions which disrupt the function of the hypothalamic melanocortin pathway...
Stephen O'Rahilly receives an award at international lipodystrophy symposium
19 November 2024
Congratulations to Professor Stephen O’Rahilly who was presented with the Celia Carrión Pérez de Tudela Award in Lipodystrophy Research while at the AELIP 12th International Lipodystrophy Symposium in Santiago de Compostela, Spain earlier this month.
Julia Ware awarded the 2024 Milo Keynes Prize for PhD Thesis
11 November 2024
Congratulations to Dr Julia Ware (Hovorka group) who has been awarded the Milo Keynes Prize for the academic year 2024, on submission of her PhD thesis - The impact of closed-loop insulin delivery on glucose control in children and young people with type 1 diabetes mellitus: Longer-term benefits across the paediatric age-...